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Background/aim: This study aimed to evaluate the efficacy of rituximab in children with difficult-to-treat nephrotic syndrome,
considering the type of disease (steroid-sensitive or –resistant) and the dosing regimen.
Materials and methods: This multicenter retrospective study enrolled children with difficult-to-treat nephrotic syndrome on rituximab
treatment from 13 centers. The patients were classified based on low (single dose of 375 mg/m2) or high (2-4 doses of 375 mg/m2) initial
dose of rituximab and the steroid response. Clinical outcomes were compared.
Results: Data from 42 children [20 steroid-sensitive (frequent relapsing / steroid-dependent) and 22 steroid-resistant nephrotic
syndrome, aged 1.9–17.3 years] were analyzed. Eleven patients with steroid-sensitive nephrotic syndrome (55%) had a relapse following
initial rituximab therapy, with the mean time to first relapse of 8.4 ± 5.2 months. Complete remission was achieved in 41% and 36% of
steroid-resistant patients, with the median remission time of 3.65 months. At Year 2, eight patients in steroid-sensitive group (40%) and
four in steroid-resistant group (18%) were drug-free. Total cumulative doses of rituximab were higher in steroid-resistant group (p =
001). Relapse rates and time to first relapse in steroid-sensitive group or remission rates in steroid-resistant group did not differ between
the low and high initial dose groups.
Conclusion: The current study reveals that rituximab therapy may provide a lower relapse rate and prolonged relapse-free survival in
the steroid-sensitive group, increased remission rates in the steroid-resistant group, and a significant number of drug-free patients in
both groups. The optimal regimen for initial treatment and maintenance needs to be determined.
Key words: Frequently relapsing nephrotic syndrome, immunosuppressive agents, steroid-dependent nephrotic syndrome, steroidresistant nephrotic syndrome, remission

1. Introduction
Idiopathic nephrotic syndrome (NS) can be classified
according to steroid response into steroid-sensitive

nephrotic syndrome (SSNS) or steroid-resistant nephrotic
syndrome (SRNS) by the International Study of Kidney
Disease in Children (ISKDC) definitions [1]. The most
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frequent histological lesions in pediatric patients are
minimal change disease (MCD) and focal segmental
glomerulosclerosis (FSGS). Children with SSNS who may
develop steroid dependency and/or frequent relapses by
time and children with SRNS together have been recently
called difficult-to-treat NS group.
There is no consensus about treatment protocols
for difficult-to-treat NS despite the presence of various
recommendations [2,3]. Steroids are the primary treatment
option for children with NS, which can induce remission
in the majority of them. Long-term use of corticosteroids
in patients with SSNS or SRNS may lead to several
complications, including cataract, obesity, hypertension,
and decreased bone density. The addition of calcineurin
inhibitors (CNIs) or mycophenolate mofetil (MMF) could
not provide long-term remission in a group of patients
with difficult-to-treat NS. New steroid-sparing agents
have been investigated in recent years. Rituximab (RTX),
a mouse-human chimeric monoclonal antibody that binds
to the CD20 antigen expressed on B cells, has become a
substantial option in difficult-to-treat NS since 2004.
Rituximab has been found to be effective in SSNS
patients, particularly in those who had relapses despite
maintenance treatment with CNIs or MMF [4–8]. There
are inconsistent results in the SRNS group on the efficacy
of RTX [3,9–11].
Several issues remain uncertain regarding the use
of RTX in the treatment of childhood NS, such as initial
treatment doses, the number of infusions, the necessity of
additional doses, and dose intervals [5,12,13]. Also, there
are scarce data in the literature on the adverse effects of
RTX in children. Besides mild infusion reactions, lifethreatening conditions such as lung injury, myocarditis,
and encephalitis have been reported [14,15].
This study aimed to evaluate RTX’s efficacy and safety
at varying doses and intervals in children with difficult-totreat NS, particularly to assess the prevention of relapses
and relapse-free survival in the SSNS group and any
improvement or remission in the SRNS group.
2. Materials and methods
This multicenter retrospective study enrolled children
with difficult-to-treat NS on RTX treatment from 11
centers in İstanbul and two centers from the surroundings
of İstanbul, Turkey. Inclusion criteria were the following:
age between 1–18 years and being followed-up at least
one year after RTX administration. Exclusion criteria
were the presence of genetic abnormalities or secondary
NS (hypocomplementemia or immune deposits in kidney
biopsy specimens). The study flow-chart is shown in
Figure 1.
The patients were classified based on the steroid
response; steroid-dependent nephrotic syndrome (SDNS)
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Screened
(n=49)

Excluded (n=7)
-

Hypocomplementemia (n=2)
NPHS2 mutation (n=3)
ARHGAP24 mutation (n=1)
The presence of immune deposits
(n=1)

Fulfilling criteria
and consenting
(n=42)
SSNS
(n=20)

SRNS
(n=22)

Figure 1. Study flow chart. Of 49 screened patients, 42 fulfilled
the selection criteria and consent to study participation.
Exclusion criteria were the presence of genetic mutations,
hypocomplementemia, and/or immune deposits in kidney biopsy
specimens. The NPHS2 gene encodes podocin that is vital for the
normal glomerular filtration barrier in kidneys. NPHS2 mutation
causes steroid-resistant nephrotic syndrome. ARHGAP24
mutation influences podocyte cell shape and membrane
structure, can causing focal segmental glomerulosclerosis. SSNS:
steroid-sensitive nephrotic syndrome (including SDNS steroiddependent nephrotic syndrome and FRNS frequently relapsing
nephrotic syndrome). SRNS:
steroid-resistant nephrotic
syndrome.

was defined as two consecutive relapses during steroid
tapering or within 14 days of therapy cessation. Frequently
relapsing nephrotic syndrome (FRNS) was defined as
at least four relapses per year or two relapses within six
months of the initial presentation. Steroid-resistant NS
was described as no response to a 4-week course of daily
corticosteroids, followed by three methylprednisolone
pulses [16]. Complete remission was defined as a urinary
protein/creatinine ratio <0.2 mg/mg or negative or trace
dipstick on three or more consecutive days, and partial
remission was defined as a urinary protein/creatinine ratio
of 0.2–2 mg/mg and, if available, serum albumin level of
>30 g/L [1,17]. Each center decided its own dosing regimen,
including initial and maintenance doses and dose intervals
of RTX. Three of 20 SSNS and 7 of 22 SRNS patients were
not in the remission state at first RTX administration day.
Of 11 centers, four preferred to administer maintenance
doses of RTX based on B-cell depletion, seven preferred
to waiting for a new relapse or a deterioration in clinical
condition. Patients were subdivided into two groups
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according to the initial dose of RTX. The low initial dose
group described the patients who received a single dose of
RTX (375 mg/m2), whereas the patients in the high initial
dose group received 2-4 doses of RTX (each dose 375 mg/
m2) weekly or biweekly. CD19 and CD20 levels could not
be evaluated because it was not available in about half of
the patients in this multicenter retrospective study.
Clinical
findings,
medications
(including
immunosuppressive use before and after RTX
administration,
premedication,
and
antibiotic
prophylaxis) and laboratory parameters (complete blood
count, urea, creatinine, electrolytes, albumin, urinalysis,
and spot urinary protein/creatinine ratio or 24-h urinary
protein excretion) were retrieved from the patient files
and analyzed to evaluate treatment outcome and adverse
events of RTX. Treatment success was assessed as follows:
decreased or no relapses in the SSNS group, and decrease
in proteinuria, increased serum albumin levels, and partial
or complete remission in the SRNS group. Drug-free
remission was defined as no relapse without steroids and
other IS drugs, or RTX for at least 12 months.
Standard deviation scores (SDS) of height and body
mass index (BMI) were evaluated at the initial visit and
annually according to Turkish children’s growth data
[18]. The estimated glomerular filtration rate (GFR) was
calculated with the modified Schwartz formula [19].
2.1. Statistical analysis
Data analysis was carried out using SPSS software
version 26 (IBM SPSS Statistics, Armonk, NY, USA). The
normality of the data was examined by the Shapiro–Wilk
test. Continuous data were expressed as the mean ± SD
if the distribution was normal and median (minimummaximum) otherwise. The Student’s t-test was used to
compare normally distributed variables, and the Mann–
Whitney U test was used if data were not normally
distributed. Categorical variables were presented as a
number and percentage and compared using the Fisher’s
exact test (independent parameters) and the McNemar test
(dependent parameters). The Wilcoxon Signed Ranks test
was used to compare clinical and laboratory parameters at
baseline and two years in the study group. Kaplan–Meier
survival analysis was used to assess the relapse-free period.
Significance was allowed at p <0.05.
3. Results
This study included 42 children (20 SSNS (SDNS/FRNS)
and 22 SRNS) aged between 1.9 and 17.3 years. There
was no gender difference between the two groups, but the
patients with SSNS were older at the time of the first RTX
dose than the patients with SRNS (p = 0.011). A total of 37
patients had kidney biopsy; 18 showed FSGS, and 19 had
MCD. The characteristics of the patients are shown in Table
1. Before using RTX, 36, 5,14, and 11 patients received

cyclosporine A, tacrolimus, cyclophosphamide (CYP),
and MMF, respectively. Additionally, a small number of
patients received other IS agents, including levamisole or
chlorambucil. Pulse methylprednisolone was administered
to 85% of SSNS and 91% of SRNS patients (Table 1).
The use of a high initial dose (2–4 doses of 375 mg/
m2) was more frequent in the SRNS group than the SSNS
group (59% vs. 35%), but the difference was not statistically
significant (p = 0.13). However, the total number of RTX
use was significantly higher in the SRNS group than in the
SSNS group (59% vs. 10%, p = 0.001) (Table 1).
The median follow-up duration after RTX was 30.0
(ranged between 14.4 and 62) and 31.2 (ranged between
6.0 and 81.6) months in patients with SSNS and SRNS,
respectively (p = 0.57). The whole study group was
followed for at least one year, 29 patients (15 of SSNS and
14 of SRNS group) were followed for two years or longer.
One year after RTX administration, the median relapse
rate was significantly lower than those in the last year before
RTX treatment in the SSNS group (0.0 (ranged between 0
and 2) vs. 3.0 (ranged between 1 and 12), respectively).
Of 20 SSNS patients, 11 (55%) had relapse following
initial RTX treatment, and the mean time to first relapse
was 8.4 ± 5.2 months. There was no significant difference
between the low and high initial dose groups considering
relapse rate (46% vs. 71%, p = 0.37) and time to first
relapse (9.2 ± 5.5 vs. 7.4 ± 5.2 months, p = 0.52). In the
Kaplan–Meier analysis in which 20 patients with SSNS
were evaluated, the median relapse-free survival was 15
months (95% CI: 1.85–28.1), with no significant difference
between low and high initial doses of RTX (p = 0.37)
(Figure 2a, 2b).
At 1- and 2-year of follow-up, serum albumin levels
improved (3.25 ± 1.33 vs. 4.09 ± 0.89, p = 0.038), complete
remission was achieved in 41% and 36% of SRNS patients,
and partial remission in 27% and 21% of them, respectively.
In the SRNS group, high initial dose therapy provided
higher remission rates than the low initial dose therapy
(77% vs. 56%) at the first year, but the difference was not
statistically significant (p = 0.38). At the second year, the
difference disappeared between the groups (57% vs. 57%).
The median remission time was 3.65 months (ranged
between 0.2 and 33.6) among SRNS patients with complete
remission. Cessation or decrease of IS agents at 1-year
and 2-year follow-up period in both groups was shown
in Table 2. Drug-free patients were higher in the SSNS
group than the SRNS group at 2 years (n = 8, 40% vs. n =
4, 18%), but the difference was not statistically significant
(p = 0.26). One patient in the SRNS group did not have
remission, and She/she stopped being given IS drugs due
to unresponsiveness.
Patients received premedication with diphenhydramine
and acetaminophen before RTX infusion. Trimethoprim-
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Table 1. Characteristics of the patients and treatment strategies.
SSNS
N = 20

SRNS
N = 22

p value

Male/Female

15/5

12/10

0.20

Age at onset of NS (years)

9.66 ± 5.16

6.70 ± 3.33

0.68

Age at the first dose of RTX (years)

12.2 ± 3.87

8.68 ± 4.09

0.011

Biopsy results, n (%)

0.004

Minimal change disease

12 (60)

7 (32)

Focal segmental glomerulosclerosis

3 (15)

15 (68)

No biopsy performed

5 (25)

-

Oral steroids

20 (100)

22 (100)

NA

CNIs

19 (95)

22 (100)

0.47

Previous immunosuppressive treatment, n (%)

MMF

2 (10)

9 (41)

0.023

Cyclophosphamide

7 (35)

7 (32)

0.82

Levamisole

1 (5)

1 (4.5)

1.00

Chlorambucil

1 (5)

-

0.47

1-3 doses

12 (60)

18 (82)

>3 doses

5 (25)

2 (9)

Steroid toxicity*, n (%)

11 (55)

13 (59)

1.00

CNI toxicity**, n (%)

5 (25)

4 (18)

1.00

CNI dependency, n (%)

13 (65)

7 (32)

0.045

ACEI or ARB use, n (%)

9 (45)

13 (59)

0.47

375mg/m2 x 1 (Low)

13 (65)

9 (41)

375mg/m2 x 2-4 (High)

7 (35)

13 (59)

Number of pulse steroid, n (%)

0.21

Initial doses of RTX, n (%)

0.13

Total doses of RTX (overall), n (%)

0.001

1-3 doses

18 (90.0)

9 (41)

4-6 doses

2 (10.0)

13 (59)

3.0 (1-12)

-

Before RTX

96.0 (14.4-187)

51.6 (4.8-122)

0.007

After RTX

30.0 (14.4-62)

31.2 (6.0-82)

0.57

Number of relapses (A year before RTX use)
Observation period (month)

SSNS: steroid-sensitive nephrotic syndrome (including SDNS: steroid-dependent nephrotic syndrome and
FRNS: frequently relapsing nephrotic syndrome). SRNS: steroid-resistant nephrotic syndrome. RTX: rituximab.
MMF : Mycophenolate mofetil. ACEI : angiotensin-converting enzyme inhibitor. ARB : angiotensin receptor
blocker. CNI: calcineurin inhibitor. Continuous data are presented as the mean ± SD if the distribution was
normal and/or median (min-max) otherwise or n (%). *Complications induced by steroid treatments, such as
cataract, osteopenia, striae, hypertension, short stature, diabetes, and central obesity. **Complications induced by
calcineurin inhibitors, including hirsutism, acute renal failure, posterior reversible encephalopathy, and gingival
hyperplasia.

sulfamethoxazole prophylaxis for pneumocystis jirovecii
was used only in 18 patients. Adverse events were noted
mostly during infusion, such as cough (n = 5), rashes (n =

1784

4), erythema (n = 4), mild respiratory distress (n = 3), fever
(n = 2), hypotension (n = 1), nausea and vomiting (n = 1).
Long-term adverse events were hypogammaglobinemia
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Figure 2. Relaps-free survival in the SSNS group (a), and adjusted for the initial dose regimens (b). SSNS: steroidsensitive nephrotic syndrome (including SDNS: steroid-dependent nephrotic syndrome and FRNS: frequently
relapsing nephrotic syndrome).

(n = 2), encephalopathy (n = 1), and myocarditis (n = 1).
Mortality was observed in one case in the SRNS group
with hypogammaglobulinemia due to severe pneumonia,

sepsis, and dilated cardiomyopathy at 8th month after
RTX. Long-term effects of RTX use were evaluated by
linear growth, renal functions, and the presence of obesity
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and hypertension. Height-SDS, BMI-SDS, or eGFR did
not change during the 2-year follow-up, both in SSNS
and SRNS groups. However, the number of hypertensive
patients significantly decreased in the SSNS group (p =
0.021) (Table 3).

in the remission rates in the SRNS group, and reduced
number of immunosuppressant uses in the whole series,
with a low frequency of adverse events. Additionally,
the number of hypertensive patients was remarkably
decreased in the SSNS group. The optimal regimen for
initial treatment and maintenance and long-term effects of
RTX need to be determined.
Currently, long-term follow-up data of RTX treatment
in patients with difficult-to-treat NS are not available, but
there are promising outcomes, particularly in the SSNS
group. However, it is still unclear how many doses are

4. Discussion
The remarkable findings of this study were significant
declines in the number of relapses and longer relapse-free
survival in the SSNS group, notable improvement in the
serum albumin levels, decrease in proteinuria and increase

Table 2. Immunosuppressive use at 1-year and at 2-year follow-up in the study group.
SSNS

SRNS

Immunosuppressives

Before RTX

1-year
(N = 20) n (%)

2-year
(N = 15) n (%)

Before RTX

1-year
(N = 22) n (%)

2-year
(N = 14) n (%)

Steroids

20

9 (45)

6 (30)

22

14 (63)

11 (50)

CNI

19

13 (65)

11 (55)

22

12 (54)

9 (40)

MMF

2

1 (5)

1 (5)

9

6 (27)

6 (27)

Drug free (at 2 years)

-

-

8 (40)

-

-

4 (18)

SSNS: steroid-sensitive nephrotic syndrome (including SDNS: steroid-dependent nephrotic syndrome and FRNS frequently relapsing
nephrotic syndrome). SRNS steroid-resistant nephrotic syndrome. CNI: calcineurin inhibitor. MMF: mycophenolate mofetil. Data are
presented as the n (%).

Table 3. Clinical and laboratory parameters at baseline and at 2-year follow-up in the study group.
SSNS
N = 15

p value

Baseline

2-year

Height-SDS

–0.55 ± 0.99

–0.15 ± 0.96

Body mass index (kg/m2)
SDS

22.7 ± 3.78
1.17 ± 1.12

Systolic BP (mmHg)
SDS

SRNS
N = 15

p value

Baseline

2-year

0.31

–0.36 ± 1.03

–0.39 ± 0.88

0.75

23.5 ± 4.30
0.77 ± 1.21

0.46
0.83

20.1 ± 5.45
0.56 ± 0.87

19.9 ± 3.46
0.33 ± 1.33

0.37
0.51

117 ± 8
0.92 ± 0.79

112 ± 15
0.77 ± 1.22

0.40
0.59

109 ± 16
0.71 ± 1.26

110 ± 19
0.41 ± 1.24

0.72
0.46

Diastolic BP (mmHg)
SDS

77 ± 10
1.24 ± 0.96

66 ± 8
0.45 ± 0.96

0.044
0.11

69 ± 17
0.90 ± 1.32

67 ± 13
0.57 ± 1.08

0.68
0.11

Hypertension n (%)

9 (60.0)

1 (6.6)

0.021

3 (21.4)

2 (14.3)

0.25

eGFR (ml/min/1.7 m2)

140.4 ± 51.8

135.8 ± 44.4

0.60

143.7 ± 55.8

129.1 ± 39.8

0.80

Serum albumin (g/dL)

4.05 ± 0.68

4.25 ± 0.65

0.67

3.25 ± 1.33

4.09 ± 0.89

0.038

Clinical parameters

Laboratory parameters

SSNS: steroid-sensitive nephrotic syndrome (including SDNS: steroid-dependent nephrotic syndrome and FRNS: frequently relapsing
nephrotic syndrome). SRNS steroid-resistant nephrotic syndrome. SDS : standard deviation score. Data are presented as the mean±SD
or n (%). The Wilcoxon Signed Ranks Test was used to compare continuous data, and the McNemar Test was used to assess hypertension
frequency between the groups at baseline and at 2 years.
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necessary for initial therapy and maintenance. Even with
a single dose of RTX, a significant but temporary decrease
has been reported in the number of relapses in patients
with SDNS [20].
In two recent studies evaluating children with FRNS/
SDNS treated with one to four doses (375 mg/m2) of RTX,
relapse-free survival at 1 and 2 years was achieved in 50%–
70% and 41%–46% of the patients, respectively. The mean
time to first relapse was found to be 9.6 and 14.6 months.
The single dose of RTX has been reported to be associated
with a higher relapse rate and a shorter first relapse time
than those receiving 3–4 doses [21,22].
In a recently published multicenter large cohort
evaluating 511 children with complicated SDNS or
FRNS, low (375 mg/m2), medium (750 mg/m2), and
high (1125-1500 mg/m2) doses of RTX were compared
with or without maintenance immunosuppression. The
authors concluded that children who received low-dose
RTX without maintenance immunosuppression had the
shortest relapse-free survival [23].
Consistent with previous studies, relapse-free survival
was approximately 50% at 2 years in our patients with
SSNS. After the first RTX treatment, more than half (55%)
of SSNS patients relapsed, and the mean time of relapse
was 8.4 ± 5.2 months. There was no significant difference
in the relapse rate or the first relapse time between the low
and high initial RTX dose groups, which can be explained
by the fact that patients treated with high initial doses are
likely to have a more severe clinical course than the initial
low dose group. Further prospective studies with a larger
sample size are needed to assess dose-related effects.
Unlike in SSNS patients, negative response to RTX
has been reported in patients with SRNS. The first
randomized controlled trial on RTX in children with
both steroid- and CNIs-resistant NS was published by
Magnasco et al. [9]. In this study, no significant difference
in the degree of proteinuria was found after three months
between children who received only CNI and steroids
and those who received two doses of 375 mg/m2 RTX in
addition to CNI and steroids. However, in later studies,
the rates of complete or partial responses to 2–4 doses of
RTX treatment in SRNS patients seem quite useful in a
limited number of patients. Reported remission (complete
and partial) rates range between 12.3%–76.9%, and FSGS
has been associated with unresponsiveness to RTX therapy
[5,10,24–27]. It is not clear that which subgroup of SRNS
patients are better candidates for RTX due to heterogeneity
of the underlying diseases.
In the SRNS patients included in our study group,
complete remission was achieved in 41% and 36% of
patients at 1- and 2-year. Considering the low and high
initial dose of RTX, there was no significant difference
in remission rates. Other remarkable outcomes were a

significant decrease in proteinuria and an increase in
serum albumin levels, and an important rate (18%) of
drug-free SRNS patients at 2 years.
Since RTX was first used in idiopathic NS, many
different protocols (including single dose, 2 doses and 4
doses) and different dosing practices (such as 100 mg/m2,
375 mg/m2, 750 mg/m2, 1500 mg/m2) have been reported
[23]. This heterogeneity leads to difficulties in assessing
the ability of different regimens.
A single dose of RTX has been discussed in the
literature, and a higher relapse rate has been reported
compared to multiple doses of RTX. However, considering
the duration of remission, it is also seen that many patients
(75%) can be in a remission state for 4–6 months with a
single dose of RTX [20, 21].
In a recent retrospective study, four children with
SDNS and eight with SRNS received 375 mg/m2 RTX
weekly for four weeks. The authors decided to administer
RTX without considering a proteinuria-free period with
steroid therapy. In this study, overall remission rates have
been reported as 100% and 27% in the SDNS and SRNS
groups, respectively [28]. In our study, of 20 patients with
SSNS, three were no patients in remission state.
Currently, there is no consensus regarding the use of
RTX with optimal initial and maintenance dose protocols.
Although there is no strong evidence that lower doses
increase the risk of earlier relapses or higher doses are
more beneficial, the most preferred dose is 375 mg/m2
[29, 30]. In the present study, data were collected from 13
different centers retrospectively, with a dose of 375 mg/m2
and different dose intervals (weekly or biweekly).
Children with difficult-to-treat NS, especially those
with SRNS, frequently require other IS agents (including
MMF or CNIs) to maintain remission. However, there are
no clear suggestions about maintenance treatment after
the RTX regimen. Although MMF has been reported to
be effective in treating patients with SDNS, cyclosporine
A is more effective in preventing relapses after rituximab
[31,32].
Several studies reported that RTX could provide an
opportunity to decrease/discontinue IS agents even with
a single dose of RTX in the SDNS group for 4–6 months
[20]. The percentage of drug-free patients with 1–4 doses
of RTX has been reported as 24% of patients with SDNS.
In recent studies, a remarkable decrease in using steroids
(in 25% and 44% of the patients with FRNS/SDNS and
SRNS respectively) and CNIs (in 52% and 35% of the
patients with FRNS/SDNS and SRNS respectively) were
noted [8, 20, 26]. In the present study, 40% of SSNS and
18% of SRNS patients were drug-free at 2 years. CNIs were
the majority of maintenance therapy.
Rituximab is usually well tolerated in children with
NS. Some researchers reported no severe effects with using
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RTX in children with NS [21]. The most frequent adverse
events are related to infusion reactions reported 5%–53%
of frequency, such as pharyngeal paresthesia, cough,
rash, hot flush, and fever [22]. All these events efficiently
resolve with slowing infusion rate, antihistamines, and
antipyretics. More serious adverse reactions were rarely
reported, such as hypotension and anaphylactic reactions
[33]. The mortality rate is not known but, in a 2016 article,
it was reported as approximately 5% in 1 year [15]. The
long-term safety of RTX in children with idiopathic NS
is not known. Long-term serious complications include
agranulocytosis (temporarily), lung injury, arthritis,
inflammatory bowel disease, acute demyelinating
neuropathy, and serum sickness disease [14,22,34–36].
Moreover, RTX increases the risk of infections, including
sepsis, pneumonia, myocarditis, as well as prolonged
hypogammaglobulinemia [24,37–39]. In the present study,
the most frequent adverse events were rashes (19%), cough
(11.9%), and mild respiratory distress during infusion
(7.1%). Of 29 patients, two had hypogammaglobinemia
(4.7%) in the 2-year follow-up period, one of them died due
to severe pneumonia, sepsis, and dilated cardiomyopathy.
There are few data regarding blood pressure (BP) and
RTX relation. Increased BP has rarely been reported as an
adverse event during infusion [6,24]. In terms of the benefit
of RTX on BP, there are very limited data in the literature.
Rugenetti et al. [7] reported a significant reduction in
BP (particularly systolic) among 10 children with SDNS
or FRNS. In our study, the number of hypertensive
patients decreased in both groups, with a significance in
patients with SSNS (p = 0.021). The decline in the use of
immunosuppressive agents (especially steroids and CNIs)
most likely account for this beneficial effect.
This study’s strengths include the 2-year follow-up
results of two patient groups with difficult-to-treat NS
from 13 different pediatric nephrology centers and the

assessment of BP in addition to remission, relapse rate,
growth, and adverse events.
The main limitation of this study lies within its
retrospective design. Obtaining data from 13 different
centers, thus resulting in heterogeneity in RTX doses,
intervals, and monitoring of B cell depletion, is another
limitation of the present study.
In conclusion, there is widespread interest in the use
of RTX in children with difficult-to-treat NS. The results
of our study based on retrospective data support the
effectiveness of RTX for these children, with prolonging
relapse-free survival, decreased numbers of relapse
rate and hypertensive patients in the SSNS group, and
increased remission rate in the SRNS group, and decreased
need for immunosuppressants in both groups. Although
RTX is usually well-tolerated during the short-term
follow-up period, it requires close monitoring for likely
adverse events that can be fatal. In terms of establishing
a consensus on dosage and frequency of administration,
the future well-designed/prospective studies are needed to
standardize RTX treatment regimens.
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